干扰素及其相关信号通路抑制脑胶质瘤侵袭的机制

国际肿瘤学杂志››2021,Vol. 48››Issue (3): 172-175.doi:10.3760/cma.j.cn371439-20200601-00034

干扰素及其相关信号通路抑制脑胶质瘤侵袭的机制

孙彦琪, 任叶青, 郭庚^*()

山西医科大学第一医院神经外科,太原 030001

收稿日期:2020-06-01修回日期:2020-09-30出版日期:2021-03-08发布日期:2021-03-25
通讯作者:郭庚 E-mail:guogeng973@163.com
基金资助:
国家自然科学基金(81201991);中国博士后科学基金(2015M571068);中国博士后科学基金(2016T90115);山西省自然科学基金(201601D011127);山西省高等学校创新人才支持计划(晋教科)(2013-8)

Mechanism of inhibitory effect of interferon and its related signal pathway on the invasion of glioma

Sun Yanqi, Ren Yeqing, Guo Geng^*()

Department of Neurosurgery, First Hospital of Shanxi Medical University, Taiyuan 030001, China

Received:2020-06-01Revised:2020-09-30Online:2021-03-08Published:2021-03-25
Contact:Guo Geng E-mail:guogeng973@163.com
Supported by:
National Natural Science Foundation of China(81201991);China Postdoctoral Science Foundation(2015M571068);China Postdoctoral Science Foundation(2016T90115);Natural Science Foundation of Shanxi Province of China(201601D011127);Program for the Outstanding Innovation Teams of Higher Learning Institutions of Shanxi Province(2013-8)

摘要/Abstract

摘要：

胶质瘤是颅内发生率较高的肿瘤,其恶性程度高、侵袭性强、致死率高等特点使目前常规治疗方法并不能达到预期的治疗效果,极大地影响患者的生命质量。干扰素作为一种具有抗增殖、抑制血管新生、抑制侵袭等作用的蛋白质,在临床中广泛应用于各种肿瘤的治疗。不少研究表明干扰素在胶质瘤的发生发展过程中起重要作用。探讨干扰素及其相关信号通路在胶质瘤侵袭过程中的作用机制,研究新的胶质瘤治疗方案在临床治疗中显得十分必要。

关键词:胶质瘤,侵袭,干扰素

Abstract:

Glioma is a tumor with a high incidence of intracranial tumor. Because of its high degree of malignancy, strong invasiveness and high mortality, the current conventional treatment cannot achieve the desired therapeutic effect, which greatly affects the quality of life of patients. As a protein with the functions of anti-proliferation, anti-angiogenesis and anti-invasion, interferon is widely used in the treatment of all kinds of tumors in clinic. Many studies have shown that interferon plays an important role in the occurrence and development of gliomas. To explore the mechanism of interferon and its related signal pathway in the process of glioma invasion, and to study the new treatment of glioma is very necessary in clinical treatment.

Key words:Glioma,Invasion,Interferon

孙彦琪, 任叶青, 郭庚. 干扰素及其相关信号通路抑制脑胶质瘤侵袭的机制[J]. 国际肿瘤学杂志, 2021, 48(3): 172-175.

Sun Yanqi, Ren Yeqing, Guo Geng. Mechanism of inhibitory effect of interferon and its related signal pathway on the invasion of glioma[J]. Journal of International Oncology, 2021, 48(3): 172-175.

参考文献29

[1]	Chen R, Smith-Cohn M, Cohen AL, et al. Glioma subclassifications and their clinical significance[J]. Neurotherapeutics, 2017,14(2):284-297. DOI: 10.1007/s13311-017-0519-x. doi:10.1007/s13311-017-0519-xpmid:28281173
[2]	Abrams DA, Hanson JA, Brown JM, et al. Timing of surgery and bevacizumab therapy in neurosurgical patients with recurrent high grade glioma[J]. J Clin Neurosci, 2015,22(1):35-39. DOI: 10.1016/j.jocn.2014.05.054. doi:10.1016/j.jocn.2014.05.054pmid:25481268
[3]	Castro F, Cardoso AP, Gonçalves RM, et al. Interferon-gamma at the crossroads of tumor immune surveillance or evasion[J]. Front Immunol, 2018,9:847. DOI: 10.3389/fimmu.2018.00847. doi:10.3389/fimmu.2018.00847pmid:29780381
[4]	Yokota A, Hirai H, Sato R, et al. C/EBPβ is a critical mediator of IFN-α-induced exhaustion of chronic myeloid leukemia stem cells[J]. Blood Adv, 2019,3(3):476-488. DOI: 10.1182/bloodadvances.2018020503. pmid:30755436
[5]	Lohmann B, Le Rhun E, Silginer M, et al. nterferon-β sensitizes human glioblastoma cells to the cyclin-dependent kinase inhibitor, TG02[J]. Oncol Lett, 2020,19(4):2649-2656. DOI: 10.3892/ol.2020.11362. doi:10.3892/ol.2020.11362pmid:32218815
[6]	Medrano RFV, Hunger A, Mendonça SA, et al. Immunomodulatory and antitumor effects of type Ⅰ interferons and their application in cancer therapy[J]. Oncotarget, 2017,8(41):71249-71284. DOI: 10.18632/oncotarget.19531. doi:10.18632/oncotarget.19531pmid:29050360
[7]	Swiatek-Machado K, Kaminska B. STAT signaling in glioma cells[J]. Adv Exp Med Biol, 2020,1202:203-222. DOI: 10.1007/978-3-030-30651-9_10. pmid:32034715
[8]	Zhang Y, Liu Z. STAT1 in cancer: friend or foe?[J]. Discov Med, 2017,24(130):19-29. pmid:28950072
[9]	Hua L, Wang G, Wang Z, et al. Activation of STAT1 by the FRK tyrosine kinase is associated with human glioma growth[J]. J Neurooncol, 2019,143(1):35-47. DOI: 10.1007/s11060-019-03143-w. doi:10.1007/s11060-019-03143-wpmid:30993511
[10]	Zhang Y, Jin G, Zhang J, et al. Overexpression of STAT1 suppresses angiogenesis under hypoxia by regulating VEGF A in human glioma cells[J]. Biomed Pharmacother, 2018,104:566-575. DOI: 10.1016/j.biopha.2018.05.079. doi:10.1016/j.biopha.2018.05.079pmid:29800921
[11]	Arslan AD, Sassano A, Saleiro D, et al. Human SLFN5 is a transcriptional co-repressor of STAT1-mediated interferon responses and promotes the malignant phenotype in glioblastoma[J]. Oncogene, 2017,36(43):6006-6019. DOI: 10.1038/onc.2017.205. doi:10.1038/onc.2017.205pmid:28671669
[12]	Rupaimoole R, Slack FJ. MicroRNA therapeutics: towards a new era for the management of cancer and other diseases[J]. Nat Rev Drug Discov, 2017,16(3):203-222. DOI: 10.1038/nrd.2016.246. doi:10.1038/nrd.2016.246pmid:28209991
[13]	Chen J, Zhong Y, Li L. miR-124 and miR-203 synergistically inactivate EMT pathway via coregulation of ZEB2 in clear cell renal cell carcinoma (ccRCC)[J]. J Transl Med, 2020,18(1):69. DOI: 10.1186/s12967-020-02242-x. doi:10.1186/s12967-020-02242-xpmid:32046742
[14]	Yang CH, Wang Y, Sims M, et al. MiRNA203 suppresses the expression of protumorigenic STAT1 in glioblastoma to inhibit tumorigenesis[J]. Oncotarget, 2016,7(51):84017-84029. DOI: 10.18632/oncotarget.12401. doi:10.18632/oncotarget.12401pmid:27705947
[15]	Zhou P, Jiang N, Zhang GX, et al. MiR-203 inhibits tumor invasion and metastasis in gastric cancer by ATM.[J]. Acta Biochim Biophys Sin (Shanghai), 2016,48(8):696-703. DOI: 10.1093/abbs/gmw063. doi:10.1093/abbs/gmw063
[16]	Yang CH, Wang Y, Sims M, et al. MicroRNA203a suppresses glioma tumorigenesis through an ATM-dependent interferon response pathway[J]. Oncotarget, 2017,8(68):112980-112991. DOI: 10.18632/oncotarget.22945. doi:10.18632/oncotarget.22945pmid:29348882
[17]	Zhang J, Zhu ZQ, Li YX, et al. Tim-3 expression in glioma cells is associated with drug resistance[J]. J Cancer Res Ther, 2019,15(4):882-888. DOI: 10.4103/jcrt.JCRT_630_18. doi:10.4103/jcrt.JCRT_630_18pmid:31436247
[18]	Liu Z, Han H, He X, et al. Expression of the galectin-9-Tim-3 pathway in glioma tissues is associated with the clinical manifestations of glioma[J]. Oncol Lett, 2016,11(3):1829-1834. DOI: 10.3892/ol.2016.4142. pmid:26998085
[19]	Li X, Wang B, Gu L, et al. Tim-3 expression predicts the abnormal innate immune status and poor prognosis of glioma patients[J]. Clin Chim Acta, 2018,476:178-184. DOI: 10.1016/j.cca.2017.11.022. doi:10.1016/j.cca.2017.11.022pmid:29174343
[20]	Hannen R, Bartsch JW. Essential roles of telomerase reverse transcriptase hTERT in cancer stemness and metastasis[J]. FEBS Lett, 2018,592(12):2023-2031. DOI: 10.1002/1873-3468.13084. doi:10.1002/1873-3468.13084pmid:29749098
[21]	Li G, Shen J, Cao J, et al. Alternative splicing of human telomerase reverse transcriptase in gliomas and its modulation mediated by CX-5461[J]. J Exp Clin Cancer Res, 2018,37(1):78. DOI: 10.1186/s13046-018-0749-8. doi:10.1186/s13046-018-0749-8pmid:29631594
[22]	George J, Banik NL, Ray SK. Knockdown of hTERT and concurrent treatment with interferon-gamma inhibited proliferation and invasion of human glioblastoma cell lines[J]. Int J Biochem Cell Biol, 2010,42(7):1164-1173. DOI: 10.1016/j.biocel.2010.04.002. doi:10.1016/j.biocel.2010.04.002pmid:20394835
[23]	Sun G, Wang Y, Zhang J, et al. MiR-15b/HOTAIR/p53 form a regulatory loop that affects the growth of glioma cells[J]. J Cell Biochem, 2018,119(6):4540-4547. DOI: 10.1002/jcb.26591. pmid:29323737
[24]	Sarma PP, Dutta D, Mirza Z, et al. [Point mutations in the DNA binding domain of p53 contribute to glioma progression and poor prognosis][J]. Mol Biol (Mosk), 2017,51(2):334-341. DOI: 10.7868/S0026898417020185.
[25]	Shen D, Guo CC, Wang J, et al. Interferon-α/β enhances temozolomide activity against MGMT-positive glioma stem-like cells[J]. Oncol Rep, 2015,34(5):2715-2721. DOI: 10.3892/or.2015.4232. doi:10.3892/or.2015.4232pmid:26329778
[26]	Jiapaer S, Furuta T, Tanaka S, et al. Potential strategies overcoming the temozolomide resistance for glioblastoma[J]. Neurol Med Chir (Tokyo), 2018,58(10):405-421. DOI: 10.2176/nmc.ra.2018-0141. doi:10.2176/nmc.ra.2018-0141
[27]	GuhaSarkar D, Neiswender J, Su Q, et al. Intracranial AAV-IFN-β gene therapy eliminates invasive xenograft glioblastoma and improves survival in orthotopic syngeneic murine model[J]. Mol Oncol, 2017,11(2):180-193. DOI: 10.1002/1878-0261.12020. doi:10.1002/1878-0261.12020pmid:28098415
[28]	Pu W, Qiu J, Riggins GJ, et al. Matrix protease production, epithelial-to-mesenchymal transition marker expression and invasion of glioblastoma cells in response to osmotic or hydrostatic pressure[J]. Sci Rep, 2020,10(1):2634. DOI: 10.1038/s41598-020-59462-w. doi:10.1038/s41598-020-59462-wpmid:32060379
[29]	Wang H, Hou Y, Hu Y, et al. Enzyme-activatable interferon-poly(α-amino acid) conjugates for tumor microenvironment potentiation[J]. Biomacromolecules, 2019,20(8):3000-3008. DOI: 10.1021/acs.biomac.9b00560. pmid:31310511